Our renewed interest in anticholinergic bronchodilator therapy has been sparked by the
development of safe yet effective quaternary anticholinergic compounds including …

Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …

BACKGROUND: Indacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for
the treatment of COPD. METHODS: This 12-week randomised, parallel-group study …

Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator
recently approved in Europe for the treatment of chronic obstructive pulmonary disease …

The two inhaled long-acting β 2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …

Recently, the results of an interesting systematic review have shown that the use of a
combination of a longacting b2-agonist (LABA) and a long-acting antimuscarinic agent …

Chronic obstructive pulmonary disease (COPD) represents a significant cause of global
morbidity and mortality, with a substantial economic impact. Recent changes in the Global …

GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and β-
agonist activities. This was a 4-week, multicentre, randomised, double-blind, double-dummy …

Novel long-acting β 2-agonists (eg indacaterol, vilanterol, olodaterol and carmoterol) and
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …

COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …